Onconetix Stock Jumps As Realbotix AI Deal Draws SRX Cash

Onconetix Inc. stocks have been trading up by 19.74 percent following upbeat coverage highlighting its oncology pipeline potential.

Live Update At 09:18:36 EDT: On Friday, September 25, 2026 Onconetix Inc. stock [NASDAQ: ONCO] is trending up by 19.74%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

ONCO has turned into a momentum story on the chart. The stock has climbed from $0.60 on 2026/08/31 to roughly $0.91 on 2026/09/24, with spikes over $1.00, showing traders are willing to chase this AI/robotics pivot. The 5‑minute tape around $1.05–$1.15 shows tight trading ranges after an early pop, a classic consolidation after a news‑driven surge.

Under the hood, Onconetix Inc. is still a small, money‑losing name. Quarterly revenue sits near $17,120 with gross profit of just $4,303, while net loss from continuing operations is roughly -$2.87M and EBITDA is around -$2.86M. That explains the brutal margins and ugly return metrics.

But ONCO also has some balance‑sheet cushions. Cash is about $5.94M, current assets are roughly $6.52M, and the current ratio of 2.2 shows short‑term obligations are covered for now. Debt is minimal, with total liabilities around $2.96M versus equity of about $13.47M. Traders should see ONCO as a speculative restructuring and deal story, not a finished, cash‑generating business.

Why Traders Are Watching ONCO’s Realbotix Bet

What’s driving ONCO right now is not legacy revenue; it’s the Realbotix story. Onconetix Inc. is reshaping itself around AI‑powered humanoid robots and Vinci AI Vision technology by acquiring Realbotix in an all‑stock deal set to close in 2H 2026, pending shareholder and regulatory approvals. For traders, that creates a clear catalyst path: deal milestones, Nasdaq listing, and any new commercial wins.

Realbotix is not just a slide deck. The company has a live pilot with a major European telecom, using its AI humanoid robots as presenters, hosts, and brand ambassadors at events. That shows real‑world demand for the tech, even if it’s early days. If that pilot scales, ONCO gets a more credible revenue story to match the current AI hype.

The SRX Global angle adds another layer. SRX has made a strategic investment in Onconetix Inc. ahead of the Realbotix acquisition, calling Vinci AI Vision an undervalued platform with defense and surveillance uses. That’s the kind of language that wakes up momentum traders hunting the next defense‑AI crossover.

To push this pivot forward, ONCO is fronting up to $5M in non‑interest‑bearing bridge financing to Realbotix, starting with $2.5M. If the transaction closes, that note disappears, effectively pre‑funding growth and cutting cash needs at closing. If the deal fails, the loan flips to a 12% interest‑bearing note, which would weigh on a small balance sheet. So traders get both upside optionality and clear execution risk.

Conclusion

ONCO now trades like a story stock, anchored less in its tiny current revenue base and more in the promise of Realbotix’s AI humanoid robots and Vinci AI Vision platform. The recent push from the $0.60s into the $0.90–$1.10 zone lines up with news of the all‑stock Realbotix acquisition, the European telecom pilot, and the SRX Global capital coming in as a strategic backer.

For active traders, the key is to treat Onconetix Inc. like a catalyst‑driven, high‑volatility play. Watch every headline around shareholder and regulatory approvals, the timing of the 2H 2026 closing, and any updates on the telecom pilot or new defense‑surveillance discussions. Dilution from the all‑stock structure is a real factor, but it also preserves ONCO’s cash while the company leans on that non‑interest bridge financing to keep Realbotix growing.

Risk here is not subtle: ONCO is burning cash, carrying heavy losses, and leaning on a complex deal structure that must land cleanly. But that’s exactly the type of setup momentum traders scan for every day. As Tim Sykes likes to say, “I don’t fall in love with stories, I trade the price action and the catalysts.” As millionaire penny stock trader and teacher Tim Sykes, says, “Small gains add up over time; focus on building wealth gradually, not chasing jackpots.”. ONCO’s Realbotix pivot, SRX Global stake, and pending Nasdaq‑listed combination give traders a clear, event‑driven roadmap—if they respect the risk and manage their trades with discipline.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

• Penny Stocks Trading Guide
• Best Penny Stocks Under $1 to Buy Today
• Top 8 Penny Stocks to Watch on Robinhood

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

• AI Penny Stocks
• Robinhood Penny Stocks
• Top Biotech Stocks